Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2006

01-07-2006 | Preclinical study

High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer

Authors: Paul N. Span, Vivianne C.G. Tjan-Heijnen, Peggy Manders, Doorlene van Tienoven, Jeffrey Lehr, Fred C.G.J. Sweep

Published in: Breast Cancer Research and Treatment | Issue 2/2006

Login to get access
Metadata
Title
High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer
Authors
Paul N. Span
Vivianne C.G. Tjan-Heijnen
Peggy Manders
Doorlene van Tienoven
Jeffrey Lehr
Fred C.G.J. Sweep
Publication date
01-07-2006
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-9153-0

Other articles of this Issue 2/2006

Breast Cancer Research and Treatment 2/2006 Go to the issue

Preclinical study

Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1

Preclinical study

Expression of “Spot 14” (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker

Epidemiology

Interrelationships between serum leptin, IGF-1, IGFBP3, C-peptide and prolactin and breast cancer risk in young women

Epidemiology

XPD Common Variants and their Association with Melanoma and Breast Cancer Risk

Preclinical study

Comparison of HER2 status between primary tumor and disseminated tumor cells in␣primary breast cancer patients

Epidemiology

Population-based mammography screening results in substantial savings in treatment costs for fatal breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits